RT Journal Article
SR Electronic
T1 Sex and gender differences in COVID testing, hospital admission, presentation, and drivers of severe outcomes in the DC/Maryland region
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.05.21253827
DO 10.1101/2021.04.05.21253827
A1 Eileen P. Scully
A1 Grant Schumock
A1 Martina Fu
A1 Guido Massaccesi
A1 John Muschelli
A1 Joshua Betz
A1 Eili Y. Klein
A1 Natalie E. West
A1 Matthew Robinson
A1 Brian T. Garibaldi
A1 Karen Bandeen-Roche
A1 Scott Zeger
A1 Sabra L. Klein
A1 Amita Gupta
A1 for the JH-CROWN registry team
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.05.21253827.abstract
AB Background Rates of severe illness and mortality from SARS-CoV-2 are greater for males, but the mechanisms for this difference are unclear. Understanding the differences in outcomes between males and females across the age spectrum will guide both public health and biomedical interventions.Methods Retrospective cohort analysis of SARS-CoV-2 testing and admission data in a health system. Patient-level data were assessed with descriptive statistics and logistic regression modeling was used to identify features associated with increased male risk of severe outcomes.Results In 213,175 SARS-CoV-2 tests, despite similar positivity rates (8.2%F vs 8.9%M), males were more frequently hospitalized (28%F vs 33%M). Of 2,626 hospitalized individuals, females had less severe presenting respiratory parameters and males had more fever. Comorbidity burden was similar, but with differences in specific conditions. Medications relevant for SARS-CoV-2 were used at similar frequency except tocilizumab (M>F). Males had higher inflammatory lab values. In a logistic regression model, male sex was associated with a higher risk of severe outcomes at 24 hours (odds ratio (OR) 3.01, 95%CI 1.75, 5.18) and at peak status (OR 2.58, 95%CI 1.78,3.74) among 18-49 year-olds. Block-wise addition of potential explanatory variables demonstrated that only the inflammatory labs substantially modified the OR associated with male sex across all ages.Conclusion Higher levels of clinical inflammatory labs are the only features that are associated with the heightened risk of severe outcomes and death for males in COVID-19.Trial registration NAFunding Hopkins inHealth; COVID-19 Administrative Supplement (HHS Region 3 Treatment Center), Office of the ASPR; NIH/NCI U54CA260492 (SK), NIH/NIA U54AG062333 (SK).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThe data utilized were part of JH-CROWN: The COVID PMAP Registry, which is based on the contribution of many patients and clinicians and is funded by Hopkins inHealth, the Johns Hopkins Precision Medicine Program. Drs. Garibaldi, Muschelli, Robinson, Bandeen-Roche, and Gupta and Mr. Schumock received funding from the COVID-19 Administrative Supplement for the HHS Region 3 Treatment Center from the Office of the Assistant Secretary for Preparedness and Response. Drs S. Klein, Zeger and Mr. Betz received funding from the NIH/NCI funded COVID-19 Serology Center of Excellence (U54CA260492). Dr. Scully is supported by R01AI154541 (NIAID/ORWH). The funders had no role in the design, analysis, or conduct of the study or in the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by IRB00250975 at all of the participating hospitals in the Johns Hopkins Health System: Howard County General Hospital, Johns Hopkins Bayview Medical Center, Suburban Hospital, Johns Hopkins Hospital, and Sibley Memorial Hospital. It was deemed by the IRB to be minimal risk and a waiver of informed consent was granted. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this study is maintained in the Johns Hopkins Precision Medicine Analytics Platform (PMAP).